Form 4: Editas Exec Sells Shares for Tax Obligations
Insider Transaction Report
Editas Medicine's EVP and Chief Scientific Officer, Linda Burkly, sold 5,121 shares of common stock at $2.4911 per share to cover tax withholding obligations related to RSU vesting.
Summary
- Linda Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine, Inc. (EDIT), reported a sale of common stock.
- The transaction involved the disposition of 5,121 shares of Editas Medicine common stock.
- The shares were sold at a price of $2.4911 per share.
- Following this transaction, Linda Burkly beneficially owns 64,398 shares of common stock.
- The sale was executed on July 31, 2025, and was made pursuant to a Rule 10b5-1 trading plan adopted on July 3, 2023.
- This sale was not a discretionary trade by the reporting person but was necessary to meet tax withholding obligations arising from the vesting of restricted stock units (RSUs) on July 24, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine, non-discretionary sale of shares by an insider to cover tax withholding obligations related to RSU vesting, as per a pre-arranged 10b5-1 plan. It does not reflect a change in management's view of the company's prospects.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a routine insider transaction report, common across all industries, indicating a pre-planned sale of shares by an executive to cover tax obligations related to equity compensation. It does not provide specific insights into broader biotechnology or gene editing industry trends.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or insider sentiment.
- Employees: No direct impact indicated beyond the specific RSU vesting event for the reporting person.
Key Dates
| Date | Description |
|---|---|
| 07/03/2023 | Date Reporting Person adopted the durable automatic sales instruction plan (Rule 10b5-1 plan). |
| 07/24/2025 | Date restricted stock units (RSUs) vested, triggering tax withholding obligations. |
| 07/31/2025 | Date of the reported transaction (sale of common stock). |
| 08/04/2025 | Date the Form 4 filing was signed. |
Keywords
Editas Medicine, EDIT, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting, 10b5-1 Plan, Biotechnology, Gene Editing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.